LTGO Stock Forecast: Latigo Biotherapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$13
−1.81% on the day

The median 12-month analyst price target for Latigo Biotherapeutics, Inc. is $50. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 1 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$861.9M
Ticker Nerd rank
1/ 100
Median analyst target
$50
Analysts covering
4
Revenue$0.0
Operating income−$25.8M
Net income−$25.8M
Free cash flow−$21.4M
Quarterly, 4 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.8%
1M
−14.8%
From high
−48.0%
From low
+3.2%
$13
$25
Range since 7 Aug 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Latigo Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
1/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
32
Issuance
14
Value
13
Growth
10
Accruals
5
Momentum
4
Quality
4
Volatility
2

Revisions (32): Analysts have, on balance, been raising their forecasts.

Volatility (2): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

LTGO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LTGO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 7 Aug 2026Adjusted close, US dollars
$0$20$40$60$80Sep 26Oct 26Nov 26LTGOHigh $73Median $50Low $36

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4
Buy
0
Hold
0
Sell
$36
Low
$50
Median
$73
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
1 Sept 2026GuggenheimInitiatesBuy$50
1 Sept 2026JefferiesInitiatesBuy$50
1 Sept 2026Leerink PartnersInitiatesOutperform$36

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for LTGO.

Market Radar

This page is one stock. Monday covers all of them.

LTGO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

LTGO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

LTGO vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Sep 26Oct 26Nov 26LTGOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LTGO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−144.6%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Latigo Biotherapeutics, Inc. has a market value of $861.9M and an enterprise value of $91.7M.

  • Shares outstanding: 60.2M.

  • Latigo Biotherapeutics, Inc. employs 66 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

LTGO and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LTGOLatigo Biotherapeutics, Inc.$861.9M1
CRVSCorvus Pharmaceuticals, Inc.$810.0M48
ODTXOdyssey Therapeutics, Inc.$800.1M1
BBTXBambusa Therapeutics, Inc.$796.2M0
IMTXImmatics NV$863.4M22
MGTXMeiraGTx Holdings Plc$779.9M70
MTRIMentari Therapeutics, Inc.$776.4M24

Take a look at LTGO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Latigo Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about LTGO

What is the LTGO stock price forecast for 2026-2027?

The median 12-month analyst price target for Latigo Biotherapeutics, Inc. is $50, with estimates ranging from $36 to $73. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LTGO stock a buy right now?

Of the 4 analysts covering Latigo Biotherapeutics, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Latigo Biotherapeutics, Inc. 1 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LTGO?

As at 21 Nov 2026, Latigo Biotherapeutics, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (32 of 100).

Will LTGO stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts is $50, and Ticker Nerd's factor model ranks Latigo Biotherapeutics, Inc. 1 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LTGO stock forecast for 2030?

No analyst covering Latigo Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LTGO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $36 to $73 over the next 12 months.

What does Latigo Biotherapeutics, Inc. do?

Latigo Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing non-opioid pain medicines. Its current programs are built around NaV1.8 inhibitors, a class of compounds designed to interrupt pain signaling at its source while avoiding the addiction risks associated with opioid therapies.

Company

About Latigo Biotherapeutics, Inc.

Latigo Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing non-opioid pain medicines. Its current programs are built around NaV1.8 inhibitors, a class of compounds designed to interrupt pain signaling at its source while avoiding the addiction risks associated with opioid therapies. The company’s pipeline includes candidates for acute pain, chronic musculoskeletal pain, and broader acute and chronic pain applications, with oral and intravenous formulations in development. Latigo Biotherapeutics serves the pain-management market by advancing targeted therapies intended for use in settings such as postoperative care, musculoskeletal disorders, and other medically significant pain conditions. Headquartered in Thousand Oaks, California, the company operates within the biotechnology sector and is centered on creating differentiated treatments that address unmet needs in non-opioid pain control.

CEO Mr. Todd N. Smith · 66 employees · United States · https://latigobio.com